共 169 条
[21]
Pardridge WM(2012)Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura Blood 120 3603-60
[22]
Giugliani R(2019)Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura N Engl J Med 380 335-82
[23]
Yogi A(2022)Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: post-HERCULES study J Thromb Haemost 20 2810-151
[24]
Alata W(2023)Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up J Clin Oncol 41 1265-1888
[25]
Shin J-W(2022)Envafolimab: first approval Drugs 82 235-9
[26]
Zuchero YJY(2023)Ozoralizumab: first approval Drugs 83 87-2858
[27]
Edavettal S(2022)VHHs as tools for therapeutic protein delivery to the central nervous system Fluids Barriers CNS 19 79-545
[28]
Muruganandam A(2020)Identification and in vivo characterization of a brain-penetrating nanobody Fluids Barriers CNS 17 62-22
[29]
Tanha J(2022)Selection of single domain anti-transferrin receptor antibodies for blood-brain barrier transcytosis using a neurotensin based assay and histological assessment of target engagement in a mouse model of Alzheimer’s related amyloid-beta pathology PLoS ONE 17 e0276107-1265
[30]
Narang S(2011)Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target Sci Transl Med. 3 84ra44-1295